These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23077112)

  • 21. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients.
    Vees H; Senthamizhchelvan S; Miralbell R; Weber DC; Ratib O; Zaidi H
    Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):182-93. PubMed ID: 18818918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.
    Tanaka K; Yamamoto Y; Maeda Y; Yamamoto H; Kudomi N; Kawai N; Toyohara J; Nishiyama Y
    Ann Nucl Med; 2016 Feb; 30(2):89-96. PubMed ID: 26511019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging regional variation of cellular proliferation in gliomas using 3'-deoxy-3'-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study.
    Price SJ; Fryer TD; Cleij MC; Dean AF; Joseph J; Salvador R; Wang DD; Hutchinson PJ; Clark JC; Burnet NG; Pickard JD; Aigbirhio FI; Gillard JH
    Clin Radiol; 2009 Jan; 64(1):52-63. PubMed ID: 19070698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome.
    Arens AI; Troost EG; Hoeben BA; Grootjans W; Lee JA; Grégoire V; Hatt M; Visvikis D; Bussink J; Oyen WJ; Kaanders JH; Visser EP
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):915-24. PubMed ID: 24346414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas.
    Yamamoto Y; Ono Y; Aga F; Kawai N; Kudomi N; Nishiyama Y
    J Nucl Med; 2012 Dec; 53(12):1911-5. PubMed ID: 23081994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
    Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
    J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
    Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Geist C; Dahlbom M; Silverman DH; Satyamurthy N; Phelps ME; Chen W
    J Nucl Med; 2012 Jan; 53(1):29-36. PubMed ID: 22159180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
    Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
    J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
    J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.
    Pafundi DH; Laack NN; Youland RS; Parney IF; Lowe VJ; Giannini C; Kemp BJ; Grams MP; Morris JM; Hoover JM; Hu LS; Sarkaria JN; Brinkmann DH
    Neuro Oncol; 2013 Aug; 15(8):1058-67. PubMed ID: 23460322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions.
    Beauregard JM; Giraudet AL; Aide N; Hofman MS; Blum R; Drummond E; Roselt P; Hicks RJ
    Nucl Med Commun; 2013 Jun; 34(6):521-6. PubMed ID: 23542911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes.
    Nozawa A; Rivandi AH; Kanematsu M; Hoshi H; Piccioni D; Kesari S; Hoh CK
    Nucl Med Commun; 2015 Jun; 36(6):573-81. PubMed ID: 25714806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
    Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
    J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.
    Pyka T; Gempt J; Hiob D; Ringel F; Schlegel J; Bette S; Wester HJ; Meyer B; Förster S
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):133-141. PubMed ID: 26219871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
    Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
    Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma.
    Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T
    Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.